focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,166.00
Bid: 12,132.00
Ask: 12,136.00
Change: -6.00 (-0.05%)
Spread: 4.00 (0.033%)
Open: 12,180.00
High: 12,198.00
Low: 12,076.00
Prev. Close: 12,172.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: NY Seen Up As Fed Decision Week Gets Underway

Mon, 14th Sep 2015 11:12

LONDON (Alliance News) - UK stocks were mostly flat midday Monday, while Wall Street was called for a slightly positive open, with investors focusing on the Federal Reserve's two-day policy meeting concluding on Thursday as expectations for a US interest rate hike remained finely balanced.

The FTSE 100 index traded up 0.2% at 6,131.61, the FTSE 250 was flat at 16,974.03, and the AIM All-Share was flat at 733.59. In Europe, the CAC 40 index in Paris was up 0.3% and the DAX 30 in Frankfurt was up 0.4%.

US stock futures pointed to a higher open, with the Dow Jones Industrial Average seen up 0.2%, and the S&P 500 and the Nasdaq 100 both pointed up 0.3%. Wall Street closed higher Friday, with the Dow up 0.6% and the S&P 500 and the Nasdaq Composite both up 0.5%.

The Federal Open Market Committee will hold a crucial two-day monetary policy later this week, following which some market commentators believe it will announce the first US rate hike since 2006. But expectations are finely balanced going into the week, and the event is likely to heighten uncertainty in the market.

IG market analyst Joshua Mahony said a rate hike on Thursday is unlikely "given the sheer size of moving parts including a mid-selloff stock market, a waning Chinese economy, and multi-year lows in oil with an associated impact upon [US] inflation, jobs and [economic] growth."

But the analyst noted that, with the markets factoring in a 28% chance of some sort of rate hike, there is enough backing to induce major volatility come Thursday.

"The question is whether a decision not to hike will even be enough to lift global indices out of the current negative mindset that has dominated the past five months," said Mahony.

Most of the negative sentiment in the past months has been caused by concerns about the Chinese economy and the resulting sell off in Asian stock markets. On Monday, the Nikkei 225 in Tokyo closed down 1.6%, while China's major stock indices ended mixed, with the Shanghai Composite down 2.7% and the Hang Seng index in Hong Kong up 0.3%.

There were mixed economic data from the Asian giant on Sunday. Chinese industrial production was up by 6.1% year-on-year in August, according to the country's National Bureau of Statistics. This was marginally better than the 6.0% growth reported in July, but below expectations of 6.4%.

In addition, fixed-asset investment in non-rural areas of the country rose by 10.9% in the first eight months of the year, but this was below expectations of 11.1% growth and slower than the 11.2% increase measured for the first seven months.

However, retail sales in China grew 10.8% year-on-year in August, beating the 10.5% consensus and July reading.

On the London Stock Exchange, ARM Holdings was the best performer in the FTSE 100, up 2.6%.

Accendo Markets head of research Mike van Dulken said that shares in the chip designer were benefiting from some positive reviews released over the weekend of Apple's latest product launches and updates, including to the iPhone and iPad, announced at an event last Wednesday. The California-based tech giant is one of the most important customers for ARM.

Miners were pushing higher in London on Monday despite the continued worries about the Chinese economy, as expectations of further stimulus by Chinese authorities are thought to be again on the table.

Rio Tinto, up 2.2%, BHP Billiton, up 2.0%, Fresnillo, up 1.7%, Randgold Resources, up 1.4%, were among the best blue-chip performers. BHP was upgraded to Buy from Hold by Jefferies.

In the red was Glencore, down 1.7% after the multi-commodities miner said the board of the company behind the Katanga mine in the Democratic Republic of Congo, in which it holds 74%, has confirmed it will suspend copper and cobalt production at the site for 18 months. Glencore had flagged the decision last week when it announced plans to improve its financial condition.

Outside miners, RELX was up 1.0% after being upgraded to Outperform from Underperform by Exane BNP.

AstraZeneca also benefited from an broker upgrade, rising 1.3% as Deutsche Bank raised its recommendation on the stock to Buy from Hold. The bank said it was confident the company will be able to return to strong growth, with analyst Richard Parkes saying this will be driven by execution on its strategy for its growth platforms - diabetes, respiratory, Japan, emerging markets, and heart drug Brilinta - and delivery on its significantly improved pipeline.

In the FTSE 250, fund managers Henderson Group, up 2.6%, and Man Group, up 1.6%, were were in favour after Exane BNP initiated them both at Outperform.

In AIM, Motive Television was up 30%. The company said it plans to make its TabletTV product available on Apple's recently announced new Apple TV platform. TabletTV allows users to watch and record free-over-the air television without a contract or subscription. Motive Television is a registered Apple developer.

Meanwhile, HaiKe Chemical Group was down 40%. The China-based specialty chemicals company said its first half trading was in line with its expectations but said it has taken a hit so far in the second six months from the turbulence in the Chinese economy. The group said it is "at risk" of failing to achieve a full-year profit and said it recorded losses in both July and August due to the tough economic conditions.

By Daniel Ruiz; danielruiz@alliancenews.com

Copyright 2015 Alliance News Limited. All Rights Reserved.

More News
Today 10:27

AstraZeneca trials yield positive results for immunocompromised patients

(Alliance News) - AstraZeneca PLC on Thursday said results from recent trials revealed a significant reduction in cases of Covid-19.

Read more
12 May 2024 13:25

Pfizer and AstraZeneca announce new investments of nearly $1 billion in France

PARIS, May 12 (Reuters) - Leading healthcare companies Pfizer and AstraZeneca announced on Sunday new investments in France worth a total of nearly $1 billion, ahead of the start of this year's annual 'Choose France' business summit.

Read more
8 May 2024 19:10

Sector movers: Aerospace and Defence, Pharma pace gains

(Sharecast News) - London's main stock market gauges continued to push higher in the middle of the week, even as investors waited on the Bank of England's policy announcement on the following day.

Read more
8 May 2024 17:46

FTSE 100 hits record high, pound slips ahead of BoE verdict

FTSE 100 up 0.5%, FTSE 250 adds 0.4%

*

Read more
8 May 2024 16:36

London close: Stocks rise further ahead of BoE decision

(Sharecast News) - London's stock markets closed with gains on Wednesday, bolstered by a dip in the value of the pound against both the dollar and the euro.

Read more
8 May 2024 09:44

AstraZeneca says withdraws Covid vaccine "for commercial reasons"

(Alliance News) - Drugmaker AstraZeneca PLC said Wednesday that it has withdrawn its Covid vaccine Vaxzevria, one of the first produced in the pandemic, citing "commercial reasons" and a surplus of updated jabs.

Read more
8 May 2024 09:39

LONDON BROKER RATINGS: UBS raises Centrica to 'buy' from 'neutral

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
7 May 2024 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.